The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study

Bødtger, Uffe; Poulsen, Lars K.; Jacobi, Henrik H.; Malling, H.‐J.

doi:10.1034/j.1398-9995.2002.1o3532.x

Cited by 80 publications

(84 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical efficacy (reduction of symptoms and/or need for medications) has been confirmed with grass (1102,1104,(1650)(1651)(1652)(1653)(1654)(1655), birch (1650,1651,(1656)(1657)(1658)(1659), ragweed (1660), Russian thistle (1661), Parietaria pollen (1662,1663), mites (1664)(1665)(1666)(1667)(1668)(1669) and cat (1670). It should be noted that three of the studies (1104,1660,1670) clearly demonstrated that the clinical effect is dose dependent.…”

Section: Aria: 2008 Updatementioning

confidence: 97%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,754

1,761

View full text Add to dashboard Cite

Section: Aria: 2008 Updatementioning

confidence: 97%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,754

1,761

View full text Add to dashboard Cite

“…For olive pollen, preseason SCIT has shown to produce significant improvement both in nasal and bronchial symptoms, and a decrease in the consumption of rescue medication [95]. For birch pollen, SCIT induced immunological changes in T cell populations and Ig subtypes [96,97] and a reduction of symptom score for rhinoconjunctivitis and asthma and total medication score [98]. Several randomized trials have evaluated the efficacy of SCIT for grass pollen allergy in patients with chest symptoms.…”

Section: Subcutaneous Immunotherapymentioning

confidence: 99%

Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence

Domínguez‐Ortega

Delgado

Blanco

et al. 2017

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

Asthma is frequently associated with atopy, characterized by the production of specific immunoglobulin E in response to environmental allergens. Currently, two types of allergen immunotherapy (AIT) are used in clinical practice: subcutaneous and sublingual immunotherapy, both accepted as key components of the therapeutic repertoire for allergic rhinitis and conjunctivitis. However, their role in asthma remains controversial. The present document is aimed at providing the clinicians with a review of the evidence on the use of AIT in asthma, focusing on the most relevant aspects of its mechanism of action, its efficacy, and existing data on safety, tolerability, and cost-effectivity, both in pediatric and adult populations. A systematic search of MEDLINE, Cochrane, and Clinical Trials databases from 2000 to April of 2016 was carried out by a panel of experts from the Spanish Allergy and Clinical Immunology Scientific Society. Relevant studies prior to the year 2000 included in ulterior systematic reviews were also considered. More than 4000 articles were identified during the search and 241 were selected to retrieve available evidence on AIT, which was graded according to the Oxford classification. All the group members reviewed the resulting text until the final version reached the consensual agreement. A summary of recommendations on the more relevant topics are proposed. The role of AIT as a valuable therapeutic strategy for prevention of exacerbation and progressive decline in lung function is highlighted. Future research should include specific tools for asthma evaluation when assessing AIT effectiveness in asthmatic patients. ResumenEl asma se asocia frecuentemente con alergia, entendida ésta como la producción de IgE específica frente a alérgenos ambientales. Actualmente, existen dos tipos de inmunoterapia específica con alérgenos (ITE) para la práctica clínica habitual: subcutánea y sublingual, ambas indicadas en el tratamiento de la rinitis y la conjuntivitis alérgicas. Sin embargo, su papel en el asma resulta todavía controvertido. Dominguez-Ortega J, et al.

show abstract

“…21 Bødtger ve ark. 22 35 has ta da, Wal ker ve ark. 23 40 has ta da çift-kör pla se bo kon trol lü ola rak uy gula dık la rı sub ku tan ASİ so nun da semp tom lar da, ilaç ge rek si ni min de ve cilt tes ti nin re ak ti vi te sin de azalma sap ta mış lar dır.…”

Section: Tar Tiş Maunclassified

Subcutaneous Allergen-Specific Immunotherapy in Allergic Rhinitis

Aksoy¹,

Demirhan²,

Özturan³

et al. 2011

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

Ö ÖZ ZE ET T A Am ma aç ç: : Allerjik ri nit ne de niy le sub ku tan allerjen spe si fik immü no te ra pi uy gu la dı ğı mız has ta la rın im mü note ra pi son ra sı so nuç la rı nın de ğer len di ril me si. G Ge er re eç ç v ve e Y Yö ön n t te em m l le er r: : Dün ya Sağ lık Ör gü tü nün be lir le di ği kri ter le re uy gun ola rak, Ocak 2002 ile Ara lık 2008 ta rih le ri ara sın da im mü no te ra pi te da vi si uy gu lan mış ve te da vi si ta mamlan mış 42 has ta nın dos ya sı ge ri ye dö nük ola rak in ce len di. Bu na gö re sub ku tan allerjen spe si fik immü no te ra pi uygu la ma sı ön ce si ve son ra sın da ki or ta la ma semp tom şid de ti, top lam semp tom sko ru, allerjen de ri tes ti ne olan du yar lı lık, me di kal te da vi ge rek si ni mi ve vi zü el ana log ska la ile iyi leş me dü zey le ri or ta ya ko nul du.B Bu ul l g gu u l la ar r: : Ça -lış ma ya yaş la rı 10-54 (ort; 27.9 ± 10.4) ara sın da de ği şen 42 has ta (15 er kek ve 27 ba yan) alın dı. Has ta la rın %90.5'inde yıl bo yu sü ren allerjik ri nit mev cut idi. Has ta la rın %33.3'ün de ise po zi tif ai le hi ka ye si var dı. Has ta la rın ya rı sın da tek allerje ne, di ğer ya rı sın da ise bir den faz la allerje ne kar şı du yar lı lık söz ko nu suy du. Has ta la rın ço ğun da (%85.7) im mü no te ra pi de tek allerjen ku la nıl dı. An cak az sa yı da ol gu da (%14.3) pa ra lel te da vi ya pıl dı. Te da vi son ra sı hasta la rın or ta la ma semp tom şid det le rin de ki azal ma is ta tis tik sel ola rak an lam lı bu lun du (P< 0.05). Top lam semp tom skor la rı sub ku tan allerjen spe si fik immü no te ra pi ön ce sin de 6-12 ara sın da (ort; 9.50 ± 1.48) iken, te da vi so nun da 0-6 ara sı na (ort; 3.64 ± 0.94) düş tü ğü sap tan dı ve bu dü şüş is ta tis tik sel ola rak an lam lı bu lun du (P< 0.05). Sub ku tan allerjen spe si fik immü no te ra pi son ra sın da ol gu la rı mı zın %62'si me di kal te da vi ye ih ti yaç duy ma dı. Ol gu la rı mız da immü no te ra pi son ra sın da ya pı lan de ri prick tes ti ne kar şı cilt du yar lı lık la rın da, is ta tis tik sel ola rak an lam lı azal ma sap tan dı (P< 0.05). Ol gu la rı mız da sub ku tan allerjen spe si fik immü no te ra pi son ra sı iyi leş me dü zey le ri tes pi ti için ya pı lan vi ze ül ana log ska la or ta la ma de ğe ri 8.56'dan 3.17'e düş tü ve bu azal ma is ta tis tik sel ola rak an lam lı bu lun du (P< 0.05).S So o n nu uç ç: : Sub ku tan allerjen spe si fik immü no te ra pi, has ta ve dok tor açı sın dan uzun ve zah met li bir te da vi sü re ci dir. An cak, allerjik ri nit te da vi sin de doğ ru en di kas yon da ve uy gun şekil de kul la nıl dı ğın da gü ve ni lir ve et kin bir te da vi yön te mi dir A An na ah h t ta ar r K Ke e l li i m me e l le er r: : Rinit, allerjik,yılboyu; immünoterapi; deri testleri; ağrı ölçümü A AB BS S T TR RA AC CT T O Ob bj je ec ct ti iv ve e: : To eva lu a te the re sults of sub cu ta ne o us al ler gen-spe ci fic im mu not he rapy ad mi nis te red to pa ti ents with al ler gic rhi ni tis.M Ma a t te e r ri i a al l a an nd d M Me et t h ho...

show abstract

The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study

Abstract: High-dose, subcutaneous IT is efficacious and safe in patients with severe birch pollen rhinoconjunctivitis and asthma.

Cited by 80 publications

References 31 publications

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence

Subcutaneous Allergen-Specific Immunotherapy in Allergic Rhinitis

Contact Info

Product

Resources

About